FDA grants Aravive's fast-track eligibility for a research drug AVB-S6-500

recently, the Houston Aravive Bio
Medicines(The Company(announced that theFDA(which has been granted theof thedrug (fast-track eligibility) for the treatment of recurrent ovarian cancer resistant to platinum chemotherapystudies have shown that GAS6-AXL signaling is a key molecular pathway for tumor growth, metastasis, immune evasion and resistance to other anticancer drugsIn addition, AXL and GAS6 expression were associated with poor cancer prognosisAVB-S6-500 is a fusion protein of the extracellular domain of the AXL receptor with the IgG1 Fc segment, which, as a false real "bait" AXL receptor, binds high affinity to the GAS6 ligand before binding to the AXL receptor on the surface of the tumor cellThe AVB-S6-500 completely and efficiently moderates GAS6, intercepts its interaction with the AXL receptor, and then silences the signals within the AXL cell, thus blocking the activation of the GAS6-AXL signaling pathwayit is worth mentioning that the AVB-S6-500 has high affinity, and its binding strength to GAS6 is 100 times higher than that of other GAS6 mono-anti-drugs under development, thus stripping GAS6 from gas6 that has been associated with the endogenous AXL receptorforHealth(the volunteers' 1st phase of the results showed good safety of AVB-S6-500, with no severe or dose-related adverse events.) in addition,studies have shown that the AVB-S6-500 dose is associated with a decrease in the number of free GAS6 in the circulatory system Aravive expects the "circulatory free GAS6 quantity" to serve as markers for better monitoring of therapeutic responses and better selection of patient response groups The reduction in biomarkers is also associated with anti-tumor activity in aVB-S6-500 in preclinical animal studies in preclinical studies, gas6-AXL inhibition softened with a single drug (including AVB-S6-500) or a combination with various anticancer therapies (radiation therapy, immuno-oncology drugs, and drugs that affect DNA replication and repair) GAS6 / AXL inhibition also shows the strategic potential for treating certain fibrosis diseases